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ABSTRACT
In addition to being a master regulator of cell cycle progression, E2F1 regulates 
other associated biological processes, including growth and malignancy. Here, we 
uncover a regulatory network linking E2F1 to lysosomal trafficking and mTORC1 
signaling that involves v-ATPase regulation. By immunofluorescence and time-lapse 
microscopy we found that E2F1 induces the movement of lysosomes to the cell 
periphery, and that this process is essential for E2F1-induced mTORC1 activation 
and repression of autophagy. Gain- and loss-of-function experiments reveal that 
E2F1 regulates v-ATPase activity and inhibition of v-ATPase activity repressed 
E2F1-induced lysosomal trafficking and mTORC1 activation. Immunoprecipitation 
experiments demonstrate that E2F1 induces the recruitment of v-ATPase to lysosomal 
RagB GTPase, suggesting that E2F1 regulates v-ATPase activity by enhancing the 
association of V0 and V1 v-ATPase complex. Analysis of v-ATPase subunit expression 
identified B subunit of V0 complex, ATP6V0B, as a transcriptional target of E2F1. 
Importantly, ATP6V0B ectopic-expression increased v-ATPase and mTORC1 activity, 
consistent with ATP6V0B being responsible for mediating the effects of E2F1 on both 
responses. Our findings on lysosomal trafficking, mTORC1 activation and autophagy 
suppression suggest that pharmacological intervention at the level of v-ATPase 
may be an efficacious avenue for the treatment of metastatic processes in tumors 
overexpressing E2F1.
INTRODUCTION
The E2F1 transcription factor is over-expressed 
in numerous human cancers, including lung, breast and 
hepatocellular carcinomas, as well as Sporadic Burkitt’s 
Lymphomas [1–4]. The E2F1 signature is also strongly 
associated with invasive tumor progression of breast and 
bladder tumors [2, 5]. In the past, the major role reported 
for E2F1 in cancer progression was its activation of cell 
cycle progression. Activation of E2F1 is sufficient to 
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irreversibly commit cells to undergo DNA replication by 
transcriptional activation of a number of genes required 
for the G1/S transition and the coordination of mitosis 
[6, 7]. However, it is now evident that other biological 
processes associated with proliferation and malignant 
transformation are also regulated by E2F1, including 
cell growth, autophagy, invasiveness and metastasis 
[2, 8–11]. Despite the impact of these processes on cancer 
progression, the molecular mechanisms by which E2F1 
regulates these responses are still unknown.
Previously, we reported that E2F1 regulates cell 
growth, increase in cell size, through activation of 
mTORC1, a major regulator of protein synthesis and 
autophagy [8]. Consistent with this observation, tumors 
from transgenic mice in which E2F1 is overexpressed 
possess high mTORC1 activity, suggesting that the effects 
of E2F1 on tumorigenesis may be in part mediated through 
mTORC1 [4]. The mechanism by which E2F1 regulates 
mTORC1 remains unknown. Earlier we showed that E2F1 
drives mTORC1 activation independently of the canonical 
PI3K/Akt/TSC1-TSC2 pathway and demonstrated that, 
after E2F1 activation, mTORC1 co-localizes with the 
lysosomes [8]. Translocation of the mTORC1 complex 
to the lysosomes has been described as the mechanism 
by which mTORC1 interacts with and is activated by 
the small GTPase Rheb [12]. In parallel, amino acids 
activate a second family of GTPases, the Rags, which 
promote the translocation of mTORC1 to the lysosomal 
surface, a process dependent on the vacuolar H+ adenosine 
triphosphatase ATPase (v-ATPase) [13].
Lysosomes are organelles that function as the main 
catabolic compartments of eukaryotic cells and play a 
key role in the degradation of the extracellular matrix 
(ECM) [14]. Several proteases that contribute to ECM 
degradation, such as cathepsin L, B and D, are directly 
or indirectly associated with lysosomes [15]. Tumors and 
invasive cancer cells, which are dependent on effective 
lysosomal function, often show alterations in lysosomal 
volume, composition and cellular distribution [16]. In turn, 
the functionality of lysosomes is dependent on v-ATPase, 
the proton pump responsible for lysosomes’ intravesicular 
acidification [14]. V-ATPase is also essential for lysosomal 
trafficking and its inhibition blocks lysosomal maturation 
at an early endosomal stage [17, 18]. Intracellular 
lysosomal movement is achieved by the cooperation of 
microtubules, actin, and myosin filaments and requires 
the coordination of multiple signaling events including 
mobilization of Ca2+, phosphoinositides, small GTPases 
and kinesins [19, 20]. Interestingly, activation of mTORC1 
by nutrients has been correlated with the presence of 
lysosomes at the cell periphery [21].
In this study, we set out to elucidate the 
underlying molecular mechanisms by which E2F1 
mediates mTORC1 activation and autophagy repression 
in U2OS osteosarcoma cells. This led us to novel 
findings concerning the ability of E2F1 in regulating 
v-ATPase activity. By modulating v-ATPase activity, 
E2F1 re-localizes lysosomes to the cell periphery and 
provides a potential mechanism by which E2F1 drives 
invasiveness and metastasis.
RESULTS
E2F1 regulates lysosomal localization
As mTOR co-localizes with the lysosome after 
E2F1 activation, we investigated whether E2F1 activity 
affected the distribution and trafficking of lysosomes 
[8]. For this study, we used the previously reported 
U2OS ER-E2F1 stable cell line [8]. The ER-E2F1 fusion 
protein is expressed in the cytosol and the addition of 
4-hydroxitamoxifen (OHT) induces its translocation to 
the nucleus, where E2F1 regulates gene transcription. 
Analysis by immunofluorescence microscopy of 
endogenous LAMP2 protein showed that activation 
of E2F1 produced a striking change in intracellular 
distribution of LAMP2-positive vesicles. Whereas serum-
deprived cells showed a predominantly perinuclear 
distribution of LAMP2-positive particles, activation of 
E2F1 induced the relocalization of LAMP2-positive 
particles to the cell periphery (Figures 1a and 1b). We also 
followed lysosomal mobility by live imaging employing 
time-lapse microscopy in cells expressing LAMP1-GFP, 
confirming the time-dependent redistribution of lysosomes 
to the cell periphery (Supplementary movie S1). 
Consistent with E2F1 regulating this response, siRNA 
depletion of endogenous E2F1 led to the accumulation 
of enlarged LAMP2 particles, which localized in the 
perinuclear region (Figure 1c). Interestingly, inhibition of 
lysosomal movement to cell periphery by knocking down 
E2F1 also produced a strong effect on the inhibition of cell 
migration (Supplementary Figure S1). The formation of 
the enlarged LAMP2 particles due to E2F1 depletion was 
also found in human lung adenocarcinoma cell line A549, 
suggesting that such phenomenon is not cell type-specific 
(Supplementary Figure S2a–S2c). Overall, the results 
show that E2F1 activation plays a role in redirecting 
lysosomes to the cell periphery.
In parallel, mTOR immunofluorescence largely 
overlapped with LAMP2 positive marker in E2F1-induced 
cells, most likely due to a direct interaction between 
mTORC1 and lysosomes (Supplementary Figures S3a 
and S3b). As the Rag GTPase family of proteins mediates 
the interaction of mTORC1 with lysosomes in the 
presence of amino acids, we hypothesized that E2F1 could 
induce the translocation of mTORC1 to lysosomes by a 
similar mechanism. To test this model, U2OS ER-E2F1 
cells were stably transfected with FLAG-tagged RagB 
and the extent of RagB interaction with mTORC1 was 
measured in cells treated with the crosslinking reagent 
dithiobis (succinimidylpropionate) prior to lysis. The 
results from FLAG immunoprecipitation experiments 
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demonstrated that the binding of mTOR and Raptor to 
RagB was increased after E2F1 activation, demonstrating 
the translocation of both proteins to the lysosomal 
compartment (Figure 1d). These results show that E2F1 
promotes the translocation of mTORC1 into the lysosomes 
and increases the physical interaction of mTORC1 with 
the lysosomal protein RagB.
Raptor, but not mTORC1 activity, is required 
for the E2F1-regulated lysosomal movement
As E2F1 promotes lysosomal trafficking, we 
asked whether E2F1-induced mTORC1 activation 
was implicated in this process. Analysis by 
immunofluorescence microscopy of LAMP2 and mTOR 
proteins showed that treatment with rapamycin, an 
mTORC1 allosteric inhibitor, did not alter E2F1-induced 
endogenous LAMP2 or mTORC1 relocalization to 
the cell periphery, despite abrogating mTORC1 basal 
activity, as measured by S6K1 T389 and 4E-BP1 T37/
T46 phosphorylation (Figures 2a–2c). These data were 
also consistent with live-cell imaging of ectopically 
expressed LAMP1-GFP (Supplementary movie S2). To 
confirm that lysosomal localization was an mTORC1-
independent process, we investigated the effect of E2F1 
on lysosomal trafficking, in cells depleted of Raptor, an 
essential component of mTORC1. Depletion of Raptor 
impaired both mTORC1 activation, as measured by 
S6K1 T389 phosphorylation, and the movement of 
LAMP2 containing lysosomes to the cell periphery 
(Figures 2d–2f). Taken together, the results suggest 
that mTORC1 activity is not necessary for lysosomal 
Figure 1: E2F1 induces lysosomal trafficking. a, b. Serum-deprived ER-E2F1 U2OS cells were cultured in the absence (CTR) or 
in the presence of 4-hydroxitamoxifen (OHT) for 6 h. Immunofluorescence assay was performed as described in Materials and Methods 
using primary antibody against LAMP2. (b) Quantification of peripheral lysosomes localization is shown. Shown is mean ± S.E.M of 3 
independent experiments. c. U2OS cells were transfected with non target siRNA (siNT) or E2F1 siRNA. Cells were serum-deprived and 
immunofluorescence was performed as described in Materials and Methods using primary antibodies against specified proteins at 48 h 
after transfection d. Stable transfected ER-E2F1/ FLAG-RagB U2OS cells were serum deprived and cultured in the absence (−) or in the 
presence of 4-hydroxitamoxifen (+) for 6 h. Proteins were crosslinked as described in Materials and Methods and immunoprecipitated using 
FLAG antibody. Expressions of the indicated proteins were determined by Western Blot analysis.
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trafficking induced by E2F1, but that the presence of 
Raptor is required for this response.
E2F1 represses autophagy
As E2F1 regulates lysosomal trafficking and 
mTORC1 activation, we reasoned it could play a role in 
controlling autophagy. To investigate the function of E2F1 
on autophagy, cells were deprived of serum for 24 hours 
and the effect of E2F1 on the conversion of LC3-I to 
LC3- II was monitored [22]. In serum-deprived cells, we 
observed a time-dependent accumulation of LC3-II, a 
response that was markedly suppressed by activation of 
E2F1 (Figure 3a). Inhibition of LC3-II flux by the addition 
of the protease inhibitor leupeptin confirmed E2F1′s role 
as a repressor of autophagy (Supplementary Figure S4a). 
Consistent with these findings, upon serum starvation, 
LC3 and LAMP2 formed prominent punctae and localized 
throughout the perinuclear region, while in E2F1-induced 
cells, LC3 staining was more diffuse, less abundant, and 
LAMP2 vesicles were localized at the cell periphery 
(Figure 3b). Furthermore, in agreement with the autophagy 
repressor role of E2F1, E2F1 depletion by siRNA was 
associated with the accumulation of LC3-II (Figure 3c). 
The disseminated localization of LC3 found in E2F1-
activated conditions could indicate that autophagosome 
formation was inhibited by E2F1, potentially through 
the activation of mTORC1 [23]. Consistent with this 
possibility, incubation with BEZ235, a dual mTOR/PI3K 
inhibitor, totally abrogated the negative effect of E2F1 
on autophagy, as measured by the increase in LC3-II 
levels (Figure 3d). As expected, BEZ235 inhibited the 
phosphorylation of the mTORC1 targets S6K1, ULK1 and 
4EBP1 (Figure 3d). Similar results were obtained in the 
presence of rapamycin (Supplementary Figure S4b). Thus, 
these findings argue that E2F1 is a negative effector of 
Figure 2: Effect of mTORC1 activity in lysosomal trafficking. a–c. Serum-deprived ER-E2F1 U2OS cells were cultured in the 
absence (CTR) or in the presence of 4-hydroxitamoxifen (OHT) and treated or not with rapamycin (Rap) for 6 h. d–f. ER-E2F1 U2OS cells 
were transfected with non target siRNA (siNT) or Raptor siRNA (siRaptor) for 48 h. Cells were serum-deprived and treated (OHT) or not 
with 4-hydroxitamoxifen. (a, d) Immunofluorescence assay was performed as described in Materials and Methods using primary antibodies 
against showed proteins. Merge panels indicate the co-localization of antibodies signals. (b, e) Quantification of peripheral lysosomes 
localization is shown. Shown is mean ± S.E.M of 3 independent experiments. (c, f) Expression of the indicated proteins was determined by 
Western Blot analysis at 6 h after treatment.
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autophagy and suggest that the migration of lysosomes to 
the cell periphery as well as activation of mTORC1 could 
both contribute to this response.
E2F1 enhances v-ATPase activity, which 
modulates lysosomal movements and mTORC1 
activity
As v-ATPase has been functionally implicated 
in vesicular trafficking and mTORC1 signaling, 
we investigated whether E2F1 regulated v-ATPase 
activity [12, 24]. V-ATPase activity was measured by 
monitoring the pH of individual lysosomes after E2F1-
induction. Lysosomes were loaded with dextran that 
was coupled to both fluorescein isothiocyanate (FITC) 
and to rhodamine, and then the changes in fluorescence 
intensity were followed by live-cell imaging system. 
FITC fluorescence decreases with acid pH, while 
rhodamine signal acts as a pH-independent control [25]. 
Using this approach, we found that the mean pH of the 
lysosomes decreases from 4.3–4.8, in serum deprived 
cells, to 3.8–4.2 in E2F1-induced cells, suggesting that 
v-ATPase activity is enhanced by the activation of E2F1 
(Figure 4a). Consistent with this observation, activation 
of v-ATPase correlated with an increase in intra-cellular 
pH following E2F1 induction from ~6.94 to 7.07, 
as measured by using the pH-sensitive fluorescence 
dye 5-(and 6)-Carboxy SNARF-1 Acetoxymethyl Ester 
Figure 3: E2F1 represses autophagy. a, b. Serum-deprived ER-E2F1 U2OS cells were cultured in the absence (CTR) or in the 
presence of 4-hydroxitamoxifen (OHT). (a) At showed times, expression of the indicated proteins was determined by Western Blot analysis. 
(b) Immunofluorescence assay was performed as described in Materials and Methods using primary antibodies against showed proteins 
at 6 h after treatment. c. U2OS cells were transfected with non-target siRNA (siNT) or E2F1 siRNA. for 48 h and serum-depleted for 
15 h. Expression of the indicated proteins was determined by Western Blot analysis. d. Serum-deprived or amino acids/serum deprived  
ER-E2F1 U2OS cells were treated (+) or not treated (−) with 4-hydroxitamoxifen (OHT) in the presence (+) or in the absence (−) of 
Bez235. Expression of the indicated proteins was determined by Western Blot analysis at 6 h after treatment.
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(Supplementary Figure S5). The potential role of E2F1 
in the regulation of v-ATPase was further strengthened 
by siRNA-depletion of endogenous E2F1, which led to 
an increase in the lysosomal pH compared to the control 
(Figure 4b). The rise of intra-lysosomal pH could imply a 
decrease in lysosomal protease activity, in agreement with 
the finding above that depletion of E2F1 is associated 
with the accumulation of LC3-II (Figure 3c). To rule 
out the possibility that the change in v-ATPase activity 
could be mediated by mTORC1, we monitored the effect 
of rapamycin treatment on the intra-lysosomal pH. Even 
in the presence of rapamycin, intra-lysosomal pH values 
observed in E2F1-induced cells were lower than in non-
induced cells, corroborating that mTORC1 activity was 
not required for the increased proton flux into lysosomes 
(Figure 4c).
The above findings indicate that E2F1 mediates 
lysosome redistribution and increased mTORC1 signaling 
by inducing v-ATPase activation. Therefore we initially 
tested the effects of concanamycin, a specific v-ATPase 
inhibitor, on both responses [26]. The results show that 
such treatment impaired E2F1-induced redistribution of 
lysosomes to the cell periphery and promotes the formation 
of large LAMP2-positive vesicles (Figure 5a) similar 
to those detected in E2F1-depleted cells (Figure 1c). 
These vesicles may originate from the blocking of early 
endosome to lysosome maturation, due to the inhibition 
of endosomal acidification, as it has been previously 
described [18, 27, 28]. In parallel, the treatment with 
concanamycin inhibited the E2F1-induced phosphorylation 
of S6K1 T389 (Figure 5b). Accordingly, the knockdown 
of the V0 subunit C (ATP6V0C) of v-ATPase provoked 
both the formation of large LAMP2-positive vesicles and 
the inhibition of S6K1 T389 phosphorylation, thereby 
corroborating the effects obtained following concanamycin 
treatment (Figures 5c and 5d). Taken together, these 
Figure 4: E2F1 regulates intra-lysosomal pH. a. ER-E2F1 U2OS cells were loaded with dextran labeled with FITC and with 
Rhodamine B for 24 h. After 15 h of serum starvation, cells were treated (OHT) or not (CTR) with 4-hydroxitamoxifen and intra-lysosomal 
pH was measured as described in Materials and Methods. b. U2OS cells were transfected either with non target siRNA (siNT) or E2F1 
siRNA and then loaded with dextran labeled with FITC and with Rhodamine B for 24 h. Intra-lysosomal pH was measured at 48 h 
after transfection as described in Materials and Methods. c. ER-E2F1 U2OS cells were loaded with dextran labeled with FITC and with 
Rhodamine B for 24 h. After 15 h of serum starvation, cells were treated (OHT) or not with 4-hydroxitamoxifen in the presence (Rap) of 
rapamycin, and intra-lysosomal pH was measured as described in Materials and Methods.
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results demonstrate that the increase in v-ATPase activity 
is essential for E2F1-induced mTORC1 activation and 
lysosomal trafficking.
The transcriptional regulation of ATP6V0B 
subunit is involved in the mechanism of 
v-ATPase activation regulated by E2F1
Next, we investigated the mechanism by which 
E2F1 up-regulates v-ATPase activity. It is known that, in 
yeast, v-ATPase activity requires the reversible association 
of the V1 domain to the membrane inserted V0 domain 
of the v-ATPase complex (Supplementary Figure S6) 
[29]. Given that we detected an increase in the physical 
interaction between mTORC1 and Rag GTPase complex 
after E2F1 induction (Figure 1d), we tested whether 
E2F1 also induced the association of the V1 domain to 
the Rag complex. To this end, we evaluated the extent of 
RagB interaction with the C1 subunit of the V1 complex 
(ATP6V1C1) using the U2OS ER-E2F1 cells stably 
transfected with a FLAG-tagged RagB. The results from 
FLAG immunoprecipitation experiments over 6 hours of 
time showed that E2F1 promoted the association of the 
V1 subunit C, ATP6V1C1, to RagB suggesting that, in 
Figure 5: Inhibition of v-ATPase activity represses E2F1-induced mTORC1 activation and lysosomal trafficking.  
a, b. Serum-deprived ER-E2F1 U2OS cells were cultured in the absence (CTR) or in the presence of 4-hydroxitamoxifen (OHT) with or 
without concanamycin (Conc). (a) At 6 h after treatment, immunofluorescence assay was performed as described in Materials and Methods 
using primary antibodies against showed proteins. Merge panels indicate the co-localization of antibody signals. (b) Expression of the 
indicated proteins was determined by Western Blot analysis. c, d. ER-E2F1 U2OS cells were transfected with non target siRNA (siNT) 
or ATP6V0C siRNAs (siATPase) and cultured in the absence or in the presence of 4-hydroxitamoxifen (OHT). (c) At 6 h after treatment, 
immunofluorescence assay was performed as described in Materials and Methods using primary antibodies against showed proteins. 
(d) Expression of the indicated proteins was determined by Western Blot analysis at the indicated times.
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addition to mTORC1, E2F1 is also capable of recruiting 
the V1 complex to lysosomes and of activating v-ATPase 
(Figure 6a). Aldolase, a glycolytic enzyme that has been 
also reported to be associated with v-ATPase, was also 
detected in the FLAG-tagged RagB immunoprecipitate 
(Figure 6a) [30]. The results indicate that the underlying 
mechanism by which E2F1 drives v-ATPase activation is 
through the recruitment of the v-ATPase subunit V1 to the 
RagB/mTORC1 complex.
As microarray data of expression of E2F1-regulated 
genes in ER-E2F1 U2OS cells are available [31], we 
took advantage of this information and we specifically 
evaluated the changes on expression of the different 
V-ATPase subunits after OHT treatment. Analysis of the 
data pointed out that the expression of ATP6V0B subunit 
was highly increased after E2F1 induction, a result that we 
confirmed by RT-PCR analysis (Supplementary Figure S7 
and Figure 6b). Analysis of the ATP6V0B promoter by 
Figure 6: E2F1 induces ATP6V1C1 association to RagB lysosomal complex and ATP6V0B expression. a. Serum deprived 
stably transfected ER-E2F1/FLAG-RagB U2OS cells were treated with 4-hydroxitamoxifen (OHT) at the indicated times. Proteins were 
crosslinked as described in Materials and Methods and immunoprecipitated using FLAG antibody. Expressions of the indicated proteins 
were determined by Western Blot analysis. b. Serum-deprived ER-E2F1 U2OS cells were cultured in the absence (CTR) or in the presence 
of 4-hydroxitamoxifen (OHT). At the indicated times, ATP6V0B mRNA levels were measured as described in Materials and Methods. 
c. ER-E2F1 U2OS cells were co-transfected with ATP6V0B-luc reporter plasmid together with CMV-renilla, serum-deprived and treated 
(OHT) or not (CTR) with 4-hydroxitamoxifen for 10 hours. Relative luciferase activity was calculated as the ratio of firefly and renilla 
activity values. Shown is mean ± S.E.M of 3 independent experiments. d. Serum-deprived ER-E2F1 U2OS cells were treated (+) or not (−) 
with 4-hydroxitamoxifen (OHT) for 6 hours. ChIP-PCR analyses of the indicated promoters were performed as described in Materials and 
Methods. e. U2OS cells were transfected with ATP6V0B expression plasmid or vector alone and then loaded with dextran labeled with 
FITC and with Rhodamine B for 24 h. Intra-lysosomal pH was measured as described in Materials and Methods in the presence of serum. 
(f) U2OS cells were transfected with ATP6V0B expression plasmid (+) or vector alone (−) as indicated. After transfection, cells were serum 
starved for 12 hours and expression of the indicated proteins was determined by Western Blot analysis. g. Quantification of S6K1 T389 
phosphorylation is shown. Shown is mean ± S.E.M of 3 independent experiments. h. ER-E2F1 U2OS cells were transfected with non-
target siRNA (siNT) or ATP6V0B siRNA at the indicated concentrations and then, serum-deprived and treated (OHT) or not (CTR) with 
4-hydroxitamoxifen for 6 hours. Expression of the indicated proteins was determined by Western Blot analysis.
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using an ATP6V0B-luciferase reporter vector suggested 
that E2F1 modulates ATP6V0B at the transcriptional 
level (Figure 6c) [32]. To directly prove that E2F1 
regulates ATP6V0B expression through promoter 
binding, chromatin immunoprecipitation (ChIP) assays 
were performed in E2F1-activated conditions. The ChIP-
PCR amplifications were performed using PCNA and 
ATP6V0B promoter-specific primers and demonstrated 
the binding of E2F1 on both target genes (Figure 6d). We 
further evaluated whether the expression of ATP6V0B 
alone was capable of regulating v-ATPase activity. Over-
expression of ATP6V0B subunit induced a small, but 
reproducible, decrease in intra-lysosomal pH, suggesting 
a role for such subunit on v-ATPase activity (Figure 6e). 
Because of the lack of a specific ATP6V0B antibody, 
mRNA levels were measured as indicators of ATP6V0B 
expression (Supplementary Figure S8a). Consistent with 
the role of v-ATPase on the regulation of mTORC1 
activity, ATP6V0B over-expression increased S6K1 T389 
phosphorylation, while conversely, ATP6V0B depletion 
abrogated E2F1-induced S6K1 T389 phosphorylation 
(Figures 6f-6h, and Supplementary Figure S8). To 
confirm the role of E2F1 on ATP6V0B expression, we 
monitored the effect of the CDK4–6 inhibitor, Palbociclib, 
on ATP6V0B mRNA levels as well as on E2F1-induced 
phosphorylation of S6K1 T389 and 4E-BP1 T37/46. 
The results demonstrate that inhibition of E2F activity 
by impairing Rb phosphorylation, prevents the E2F1-
induced ATP6V0B mRNA production as well as mTORC1 
activation (Supplementary Figure S9). Overall, results 
here point out that expression levels of ATP6V0B subunit 
can regulate both v-ATPase and mTORC1 activities and 
that induction of ATP6V0B by E2F1 could be responsible 
for the effect of E2F1 on both processes.
DISCUSSION
Oncogenic events affect multiple intracellular 
signaling networks that involve interconnections and 
crosstalk between the individual signaling pathways. 
Integration of these networks defines the hallmarks that 
characterize tumor cells [33]. Traditionally E2F1 has been 
recognized as a critical regulator of cell cycle progression, 
through its ability to regulate the G1/S transition and 
S-phase entry [6, 7]. However, it has become increasingly 
evident that additional biological processes associated with 
malignant transformation are regulated by E2F1, including 
cell growth, autophagy, invasiveness and metastasis 
[2, 8–11]. In spite of the importance of these processes, 
the molecular mechanisms by which E2F1 modulates 
these responses is not extensively understood. Here, we 
demonstrate that E2F1 regulates the activity of v-ATPase, 
the major regulator of the lysosomal pH. By modulating 
this activity, E2F1 is capable of regulating lysosomal 
biology. This leads to the activation of mTORC1 and 
the relocalization of lysosomes to the cell periphery, 
required for cells to establish an acidic and active protease 
environment needed for promoting invasiveness and 
metastasis (Figure 7).
In this study, we reveal that E2F1 is able to regulate 
endosomal trafficking and re-direct lysosomes to the cell 
periphery. Localization of lysosomes at the periphery of 
cells has been mostly associated with invasive growth, 
angiogenesis and more recently, regulation of mTORC1 
activity [16, 21]. Here, we demonstrate that activation of 
E2F1 induces mTORC1 translocation to lysosomes, where 
it is activated. We show that the intracellular acidification 
is not responsible for the peripheral movement 
of lysosomes induced by E2F1, as reported for the 
Figure 7: Involvement of v-ATPase on E2F1′s functions. Schematic overview showing the mechanism by which E2F1 can 
regulate cellular growth, autophagy, invasiveness and metastasis.
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nutrient-induced lysosomal localization [21]. In contrast, 
E2F1 causes an alkalization of intracellular pH. Others 
have shown that intracellular pH of tumor cells is more 
elevated than untransformed controls, and importantly, 
this increase is sufficient to induce tumorigenicity in 
cultured fibroblasts [34]. It is known that E2F1 induces 
the transcriptional upregulation of key enzymes of the 
glycolytic pathway, shifting the energy production from 
oxidative phosphorylation to anaerobic glycolysis [35]. 
This produces an excess of lactate and an intracellular 
acidosis. Our results suggest that, in order for a cell to 
survive acidosis, E2F1 induces a proton-transfer from the 
cytoplasm to internal vesicles and to extracellular medium.
Lysosomes are not only essential for trafficking 
endosomal cargo but also for the autophagy process. In 
response to serum deprivation, lysosomes accumulate 
in the perinuclear area to facilitate their fusion with 
autophagosomes and consequently promote autophagy. 
This process is triggered by inhibition of mTORC1, 
which is essential for autophagosome formation [36]. In 
agreement with the action of E2F1 in driving lysosomes 
to cell periphery and also activating mTORC1, we 
demonstrated here that activation of E2F1 represses 
autophagy. Until now, the role of E2F1 in autophagy has 
been controversial. Some reports point out that E2F1 
promotes autophagy by upregulating the expression of 
autophagy genes such as LC3, ATG1, ATG5 and DRAM 
[9]. On the other hand, others show that downregulation of 
E2F1 results in high levels of autophagy and they suggest 
that regulation of Bcl2 expression by E2F1 is involved 
in this process [10]. Our finding that E2F1 represses 
autophagy supports the model that genes involved in the 
upstream inhibition of mTORC1 signaling, including 
PTEN, TSC1, and TSC2, stimulate autophagy and, 
conversely, mTORC1-activating oncogenes, such as class 
I PI3K and Akt inhibit autophagy [23].
Increased E2F1 activity induced lysosomal 
acidification, while depletion of the endogenous transcript 
produced alkalization of these vesicles, confirming 
this response also occurs at physiological E2F1 levels. 
Since v-ATPase is the main contributor for maintaining 
the intracellular acidic milieu of lysosomes, our results 
imply that v-ATPase activity is modulated by E2F1 [14]. 
Activation of v-ATPase is associated with a number 
of cellular processes related to lysosomal biology, 
including mTORC1 regulation and endosomal/lysosomal 
trafficking [13, 18]. We demonstrate that inhibition of 
v-ATPase activity by treatment with v-ATPase inhibitor 
concanamycin A, or by depletion of the essential subunit 
for v-ATPase function, APT6V0C, abolished both 
processes, indicating an essential role for v-ATPase on 
functions regulated by E2F1 activity.
The v-ATPase holoenzyme consists of a membrane 
inserted V0 domain, which is responsible for the proton 
pore and a peripheral V1 domain responsible for ATP 
hydrolysis. Reversible association of V1 and V0 domains 
has been reported as the main mechanism of v-ATPase 
regulation [37]. In agreement, we demonstrated that 
acidification of lysosomes by E2F1 action is accompanied 
by the association of the C1 subunit of the V1 domain, 
ATP6V1C1, to v-ATPase/RagB lysosomal complex, 
suggesting that E2F1 could modulate v-ATPase activity 
through the mechanism of V1 and V0 domain reversible 
association. It was previously demonstrated that v-ATPase 
can regulate the translocation of mTORC1 to lysosomes 
through RagB activity modulation, as in the case of 
mTORC1 regulation by amino acids [13]. Here, we show 
that E2F1 induced an increase in the binding of mTORC1 
to RagB, suggesting that once v-ATPase is activated by 
E2F1, RagB is needed for the of recruitment mTORC1 to 
lysosomes and for mTORC1 activation.
E2F1 activation induced the expression of the 
v-ATPase subunit, ATP6V0B, whose overexpression 
produced an increase in v-ATPase activity and mTORC1 
activation, even though to a smaller extent compared to 
that of E2F1 over-expression. This indicates that other 
mechanisms might be involved in the regulation of both 
processes by E2F1. As far as we know, this is the first 
report demonstrating that over-expression of one v-ATPase 
subunit can regulate v-ATPase activity in mammals. 
Previously, another v-ATPase subunit, ATP6V1C1, has 
been described to play an essential role in the reversible 
assembly of the v-ATPase complex and its activation in 
yeast [32]. Interestingly, overexpression of the ATP6V1C1 
subunit has been detected in several tumors such as oral 
squamous, pancreatic and hepatocellular carcinomas [38–
40]. Moreover, increased ATP6V1C1 subunit expression 
levels were found to be associated with metastatic 
potential of tumors [39] and, in agreement with these 
findings, depletion of ATP6V1C1 subunit by siRNA 
resulted in the suppression of growth and metastasis in in 
vitro and in vivo models of hepatocellular carcinoma [40]. 
It will be critical to elucidate, in future studies, whether 
ATP6V0B could also play a similar role in tumors.
The invasive phenotype has been correlated with 
alteration of lysosomal trafficking and with high levels 
of v-ATPase activity [16]. A variety of cancer cells 
secrete lysosomal proteases such as cathepsins, which 
contribute to the degradation of extracellular matrix [41]. 
Thus, v-ATPase activity is necessary for acidification 
of the extracellular medium that allows an optimal pH 
for proteases to be active and induce the degradation of 
extracellular matrix. Our findings demonstrate that E2F1 
regulates the movement of lysosomes to the cell surface, 
which will help to better understand the role of E2F1 in 
invasion and metastasis. Several studies indicated a strong 
association between E2F1 expression and metastasis. For 
example, deregulation of E2F1 enhanced invasion and 
metastasis of malignant melanoma without affecting 
proliferative activity [11]. Moreover, E2F1 is expressed 
at considerably higher levels in metastatic than in primary 
tumors of melanoma patients [11]. Importantly, both 
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expression of E2F1 and the gene expression signature 
reflecting activation of E2F1 are strong predictors of 
progression of superficial bladder tumors to invasive 
tumors. From the results obtained in this study, we propose 
that pharmacological inhibition of v-ATPase should be 
tested with the aim to inhibit metastatic processes in 
tumors overexpressing E2F1.
MATERIALS AND METHODS
Cell culture and chemicals
Osteosarcoma cell line U2OS was purchased from 
American Type Culture Collection and stable transfected 
ER-E2F1 U2OS was established previously in our 
laboratory [8]. Cell lines were cultured in DMEM media 
containing 10% fetal bovine serum. Unless indicated 
otherwise, cells were serum-starved overnight before 
starting the experiments. ER-E2F1 translocation to the 
nuclei was achieved by incubating cells with 400 nM 
of 4-hydroxytamoxifen (OHT) (Calbiochem, USA). 
For assays using inhibitors, cells were pre-incubated for 
30 minutes in serum-starved media in the presence of 
Rapamycin (Sigma-Aldrich, USA), BEZ235 (Novartis, 
Switzerland), Concanamycin A (Sigma-Aldrich, USA) and 
Palbociclib PD-0332991 (Selleckchem, USA).
siRNAs, plasmids, transfection and luciferase 
activity
The following siRNAs were used: non-
silencing CTR (GCAUCAGUGUCACGUAAUA) 
and ATP6V0B (GAUUUGGGCUUCCGCUUUGAU, 
AUCAAAGCGGAAGCCCAAAUC) siRNAs 
were purchased from Sigma-Aldrich (USA) ; E2F1 
siRNA (sc-29297) was purchased from Santacruz 
Biotechnology (USA); Raptor (L-004107–00-0005) 
and ATP6V0C (L-017620–01-0005) siRNAs were 
purchased from Thermo Scientific (USA). ATP6V0B-
pLX304 was purchased from DNASU (Arizona State 
University). LAMP1-GFP was purchased from Addgene 
(USA). ATP6V0B-luciferase vector was obtained by 
subcloning a 685 bp genomic fragment of the human 
gene ATP6V0B 5′ UTR-flanking region into the NheI 
and BglII sites of pGL3-Basic luciferase reporter vector 
(Promega, USA) [32]. The integrity of ATP6V0B-luc 
construct was confirmed by sequencing. Cells were 
transfected using lipofectamine 2000 according to the 
manufacturer instructions. For the luciferase assay, cells 
were co-transfected with ATP6V0B-luc and CMV-Renilla 
control plasmid, and luciferase and renilla activities were 
determined by using Dual-Luciferase Reporter Assay 
System according to manufacturer instructions (DLR 
assay system, Promega, USA).
Quantitative real-time PCR
Following treatment, total RNA was extracted 
using Trizol (Invitrogen, USA). 1 μg of total RNA was 
subjected to reverse transcription and the resulting 
cDNA samples were used (diluted 1:100) in PCR 
amplification using LightCycler® 480 SYBR Green 
I Master (Roche Applied Science, USA). Calculation 
of relative mRNA was done using Light Cycler 480 
software. The following primers were used: ATP6V0B, 
5′-ATCATCTTCTGTGAGGCTGTGGC-3′ (forward), 
and 5′-AGACTCCACAGAAGAGGTTAG ACAG-3′ 
(reverse); Actin, 5′-AATGTGGCCGAGGACTTTGATTG 
C-3′ (forward), and 5′-AGGATGGCAAGGGACTTCCT 
GTAA-3′ (reverse).
Western blot
Protein extraction, separation and detection were 
achieved as described before [8]. The following antibodies 
were used: anti-human E2F1 (1:500), anti-S6K1 
(1:3000) and anti-Aldolase B (1:1000) from Santacruz 
Biotechnology (USA), anti-LC3 (1:2000) from MBL 
International (Germany), anti-FLAG (1:5000) from Sigma 
Aldrich (USA), anti-ATP6V1A (1:2000) from Thermo 
Scientific (USA), anti-ATP6V1C1 (1:1000) from Aviva 
Systems Biology (USA), anti-raptor (1:1000) from 
Millipore (USA), anti-pS6K1 (1:2000), anti-p4EBP1 
(1:3000), anti-mTOR (1:1000), anti-pRb (1:1000) and 
anti-actin from Cell Signaling Technology (USA).
Live-cell imaging analysis of lysosomal 
trafficking
ER-E2F1 U2OS cells were plated in 8 wells 
chamber slide (Ibidi) and transiently transfected for 24 h 
to express LAMP1-GFP. After overnight serum starvation, 
cells were treated as described. Fluorescence was analyzed 
on the Leica TCS SP5 spectral Live confocal microscope 
using a 63X N.A 1.4 objective and LAS AF software, 
within an incubation chamber XL LSM710 S1 (PeCon 
GmbH, Germany) with a heating insert P-LabTek S1. GFP 
fluorophore was excited with Argon laser 15%. Time-lapse 
images were taken from six regions for each sample every 
minute for 20 hours. Images were analyzed with ImageJ 
software and converted into avi format to be edited with 
Final Cut software.
Measurement of lysosomal pH in live cells
ER-E2F1 U2OS cells were plated in 8 wells 
chamber slide (Ibidi) and loaded with a 70, 000-Da dextran 
that was coupled to FITC and to Rhodamine (Fluorescein 
isothiocyanate–dextran, Rhodamine B isothiocyanate 
Dextran) (Sigma-Aldrich, USA) at 1 mg/ml during 
20 hours in serum starved conditions. After washing, cells 
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were treated as indicated. Fluorescence was analyzed on 
the Leica TCS SP5 spectral Live confocal microscope 
using a 63X N.A 1.4 objective and LAS AF software. 
Time-lapse images were taken from six regions for each 
condition every minute during 20 hours using excitation 
wavelengths of 488 for FITC and 568 for Rhodamine. The 
fluorescence intensity of the images was analyzed using 
ImageJ software. As a result, the red and green signals as 
a function of time were obtained. These curves featured 
a noisy pattern, so that each of them was smoothened 
by a polynomial interpolation. The green-to-red ratio was 
computed from each of these smoothened curves and then 
from these an average curve with standard deviation was 
computed for all six positions. Calibration was performed 
by incubation of the cells with media adjusted between 5.0 
to 8.0 pH values containing 10 μM of nigericin (Panreac 
Sciences, Spain) and 10 μM Valinomycin (Sigma-
Aldrich, USA).
Measurement of intracellular pH
Intracellular pH was measured as previously 
described [42]. Briefly, ER-E2F1 U2OS cells were treated 
as described, resuspended in PBS and loaded with 5 μM 
of 5-(and 6)-Carboxy SNARF-1 Acetoxymethyl Ester 
(SNARF-1, AM) (Molecular Probes, USA) for 30 min 
at 37 °C. Finally, the cells were washed and run on a 
MoFlo Astrios Cell Sorter (Beckman Coulter, USA) at 
an excitation wavelength of 488 nm and an emission of 
576 nm and 664 nm using linear amplification. The ratio 
664/576 was determined to normalize the fluorescence 
intensity. Calibration curve was performed by incubation 
of the cells with high-K+ calibration buffers adjusted 
between 6.0 to 8.0 pH values containing 10 μM of 
Nigericin (Panreac Sciences, Spain).
Immunofluorescence analysis
Cells were plated onto glass coverslips and 
procedure was achieved as described previously [8]. The 
following antibodies were used: mTOR rabbit monoclonal 
(dilution 1:150) from Cell Signaling Technology (USA); 
LAMP2 mouse monoclonal (dilution 1:300) from BD 
Biosciences (USA); LC3 rabbit polyclonal (dilution 1:300) 
from MBL International (Germany).
Fluorescence was detected with the Leica spectral 
confocal microscope TCS SP5 using a 63X N.A 1.4 
objective and LAS AF software. Fluorophores were 
excited with Argon laser 15% for 488 nm, DPSS 561 for 
555 nm and Diode laser for 405 nm. Images were analyzed 
with ImageJ software.
Cross-linking and immunoprecipitation
After the treatment, U2OS cells stably expressing 
FLAG-RagB and ER-E2F1 were washed twice with 
ice-cold PBS and incubated for 7 minutes at room 
temperature with 1 mM DSP crosslinker reagent in PBS 
(Thermo Scientific, USA). 1 M Tris-HCl (pH 7.5) was 
added 1:10 to quench DSP and cells were washed twice 
prior to lysis in ice-cold RIPA buffer (1% NP-40, 1% 
deoxycholate, 0.1%SDS) in the presence of protease and 
phosphatase inhibitors cocktails (Sigma Aldrich, USA). 
The soluble fractions from cell lysates were isolated by 
centrifugation at 13, 000 rpm for 5 minutes in a microfuge. 
For immunoprecipitations, 30 μl of a 33% slurry of anti-
FLAG M2 beads (Sigma Aldrich, USA) was added to 
each lysate and incubated with rotation overnight at 4°C. 
Immunoprecipitates were washed three times with RIPA 
buffer supplemented with 500 mM NaCl and once with 
normal RIPA buffer. Immunoprecipitated proteins were 
resolved by 4%–20% SDS-PAGE.
Migration assay
Cell migration was dynamically recorded using 
the xCELLigence RTCA-DP system (Roche, Germany) 
following the manufacturer instructions. 25, 000 cells were 
plated in the upper chamber coated with collagen-type I 
and the migration into the bottom chamber, in response 
to fetal serum as a chemoattractant, was monitored 
during 24 hours. The electrical impedance caused by the 
migration of the cells from the upper chamber to the lower 
chamber is converted to Cell Index Value. Thus, the Cell 
Index is an indicator of the cell capacity to invade the 
matrix and migrate. The RTCA Software 1.2 was used to 
analyze the data.
Chromatin immunoprecipitation assays
Chromatin immunoprecipitation assays were 
performed following the Standard ChIP protocol from 
Millipore. Briefly, cells were treated with formaldehyde 
(final concentration 1%) to crosslink chromatin 
and harvested. Cell lysates were then prepared and 
sonicated on ice to break chromatin DNA to an 
average length of 500 bp. Cell lysates (from 4 × 106 
cells per sample) were incubated with 2 μg of E2F1 
antibody (KH95, Santa Cruz Biotechnology). DNA 
amplification of the captured DNA immunocomplex 
was performed using primers complementary to the 
ATP6V0B and PCNA-promoter regions harboring 
putative E2F1-binding sites. The primer sequences were 
5′-AGCGTCGCCTTGCTCTAGAC-3′ as forward and 
5′-AAGACCCCGGAGTAGAGCAGTG-3′ as reverse to 
generate a 228 bp amplification product for ATP6V0B 
promoter; 5′-TTCTCATTGGCCTGCCACGC-3′ as 
forward and 5′-ACCACCCGCTTTGTGACTTTG-3′ 
as reverse to generate a 117 bp amplification product 
for PCNA promoter. DNA samples were analysed 
by electrophoresis on 2% agarose gels, stained with 




Data was analyzed by GraphPad Prism4 software. 
Results were presented as Mean (S.E.M for n = 4. 
Experimental data sets were compared by a two-sampled, 
two-tailed and unequal S.D. Student t Test. Values of 
*P(0.05, **P(0.005 and ***P(0.0005 were considered 
statistically significant.
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